EUVIMEDFaigh amach EUVIMED
CrossrefCárta eolais

Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report

Lingfen Zeng, Jieming Sun

Clinical Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/ccr3.73834 ↗
AchoimreSonraí leabharliosta

Achoimre

ABSTRACT Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism. Clinicians should closely monitor plasma glucose during and after ICI therapy.

Eolas a oireann do do chuid oibre.

Ó thús saor in aisce agus taighde litríochta pearsanta go dtí an Research Suite iomlán.

Féach ar na taraifí →

An bhfuil gach téacs iomlán ó fhoilsitheoirí san áireamh?

Ní hea. Is ábhair éagsúla iad tagairtí bibleagrafaíocha, achoimrí agus lánthéacsanna. Braitheann fáil an lánthéacs ar an bhfoinse, Open Access agus ar na ceadúnais atá agat cheana. Ní chuireann taraif EUVIMED cearta breise foilsitheora ina n-ionad.

Féach ar na taraifí →